Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months af­ter Gilead gut­ted its rich part­ner­ship with Gala­pa­gos fol­low­ing a bit­ter set­back at the FDA, the Bel­gian biotech is hun­ker­ing down and chop­ping the pipeline in an ef­fort to con­serve cash while their BD team pur­sues a mis­sion to find a “trans­for­ma­tive” deal for the com­pa­ny.

The fil­go­tinib dis­as­ter didn’t war­rant a men­tion as Gala­pa­gos laid out its Dar­win­ian re­struc­tur­ing plans. Forced to make choic­es, the com­pa­ny is ditch­ing its IPF mol­e­cule ’1205, while mov­ing ahead with a Phase II IPF study for its chiti­nase in­hibitor ’4617.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.